Hepion Pharmaceuticals Management
Management criteria checks 2/4
We currently do not have sufficient information about the CEO.
Key information
John Brancaccio
Chief executive officer
US$81.0k
Total compensation
| CEO salary percentage | n/a |
| CEO tenure | less than a year |
| CEO ownership | 0.006% |
| Management average tenure | no data |
| Board average tenure | 2yrs |
Recent management updates
Recent updates
CEO
John Brancaccio (76 yo)
less than a year
Tenure
US$81,000
Compensation
Mr. John Patrick Brancaccio, C.P.A, serves as Independent Non-Executive Director at Tiziana Life Sciences plc since July 2020. He is an Independent Non-Executive Director at OKYO Pharma Limited since June...
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Interim CEO | 11.5yrs | US$81.00k | 0.0060% € 223.9 | |
| Independent Director | 11yrs | US$72.90k | 0.0060% € 223.9 | |
| Member of Scientific Advisory Board | 1.7yrs | no data | no data | |
| Member of Scientific Advisory Board | 1.7yrs | no data | no data | |
| Scientific Advisory Board Chair | 5.3yrs | no data | no data | |
| Member of Scientific Advisory Board | 1.7yrs | no data | no data | |
| Member of Scientific Advisory Board | 8.3yrs | no data | no data | |
| Independent Director | less than a year | no data | no data | |
| Member of Scientific Advisory Board | 1.7yrs | no data | no data | |
| Independent Director | 2.4yrs | US$80.50k | no data |
2.0yrs
Average Tenure
68yo
Average Age
Experienced Board: 336's board of directors are not considered experienced ( 2 years average tenure), which suggests a new board.